Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
108 studies found for:    GBA
Show Display Options
RSS Create an RSS feed from your search for:
GBA
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)
Condition: Gaucher Disease
Intervention: Drug: Imiglucerase
2 Unknown  Intra-monocyte Imiglucerase Kinetics in Gaucher Disease
Condition: Gaucher Disease
Intervention: Drug: Imiglucérase (drug) pharmacokinetics
3 Completed
Has Results
Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
Condition: Gaucher Disease, Type 1
Interventions: Biological: velaglucerase alfa;   Biological: imiglucerase
4 Completed
Has Results
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)
Condition: Gaucher Disease, Type 1
Interventions: Drug: Eliglustat tartrate;   Drug: Imiglucerase
5 Completed
Has Results
Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease
Conditions: Gaucher Disease, Type 1;   Cerebroside Lipidosis Syndrome;   Glucocerebrosidase Deficiency Disease;   Glucosylceramide Beta-Glucosidase Deficiency Disease;   Gaucher Disease, Non-Neuronopathic Form
Intervention: Drug: Cerezyme
6 Recruiting GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3
Condition: Gaucher Disease
Interventions: Drug: GZ/SAR402671;   Drug: Imiglucerase
7 Withdrawn Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients
Condition: Parkinson's Disease
Interventions: Biological: AFFITOPE® PD01A + Adjuvant;   Biological: Adjuvant without active component
8 No longer available Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease
Condition: Gaucher Disease
Intervention: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD)
9 Completed Bone Response to Enzyme Replacement in Gaucher's Disease
Condition: Gaucher's Disease
Intervention: Drug: CEREDASE™
10 Completed
Has Results
A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
Condition: Gaucher Disease
Intervention: Drug: Taliglucerase alfa
11 Recruiting Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)
Condition: Gaucher Disease Type 1
Intervention: Drug: N-acetylcysteine
12 Completed Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease
Condition: Gaucher Disease, Type 1
Intervention: Drug: ISU302
13 Completed Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients
Condition: Gaucher Disease
Intervention: Drug: PRX-112
14 Completed
Has Results
A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
Condition: Gaucher Disease
Intervention: Drug: Taliglucerase alfa
15 Withdrawn The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease
Condition: Gaucher Disease
Interventions: Drug: Cerezyme®;   Drug: ISU302
16 Completed
Has Results
An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease
Condition: Gaucher Disease, Type 1
Intervention: Biological: VPRIV®
17 Completed
Has Results
Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial
Condition: Gaucher Disease
Intervention: Drug: Taliglucerase alfa
18 Completed
Has Results
Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase
Condition: Gaucher Disease
Intervention: Drug: Taliglucerase alfa
19 Unknown  Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C
Conditions: Gaucher Disease;   Hepatitis C
Intervention:
20 Completed
Has Results
Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)
Condition: Gaucher Disease
Intervention: Drug: GA-GCB

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.